GET DAILY SIGNALSSepterna (SEPN) Q3 2026 Earnings: Collaboration Momentum and Cash Position Under the Microscope
Key Takeaways
- Septerna reported third-quarter 2026 revenue of $18.9 million, down from $21.5 million in the same period a year earlier.
- The company posted a net loss of $26.6 million, or $0.57 per diluted share, compared with net income of $8.2 million, or $0.18 per share, in Q3 2025.
- Research and development (R&D) expenses rose roughly 51% year over year to $36.6 million, the primary driver of the wider loss.
- Cash, cash equivalents, and marketable securities totaled $565.2 million as of September 30, 2026, with a runway projected into mid-2029.
- Revenue continued to be driven by the Novo Nordisk collaboration, including milestone achievements and research services.
Why These Results Matter for Investors
Septerna is a clinical-stage biotechnology company focused on oral small-molecule medicines targeting GPCRs, a broad family of proteins linked to numerous diseases. With no product revenue yet, quarterly updates are evaluated mainly on collaboration income trends, R&D spending patterns, and cash reserves. The Q3 2026 figures come after a strong stock advance, so they serve as an important check on whether pipeline investments are generating the clinical and partnership progress needed to support current valuations.
Breaking Down the Quarter
Septerna recorded revenue of $18.9 million for the quarter ended September 30, 2026, versus $21.5 million in Q3 2025. This included $2.7 million from amortization of the $195.0 million upfront payment from Novo Nordisk, $5.2 million tied to research milestones, and $11.0 million from collaboration research services. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company moved to a net loss of $26.6 million, or $0.57 per diluted share, from net income of $8.2 million, or $0.18 per diluted share, a year earlier. The prior period included a $12.5 million gain on a non-financial asset sale. R&D costs climbed to $36.6 million from $24.3 million, and general and administrative expenses increased to $9.6 million from $7.1 million.
Septerna closed the quarter with $565.2 million in cash, cash equivalents, and marketable securities, and it confirmed its cash runway should extend at least into mid-2029.
Market Reaction and What Investors Are Watching
Heading into the release, SEPN shares had already posted a notable gain and were trading near 52-week highs. Focus centered less on the expected loss and more on collaboration updates with Novo Nordisk and the company’s ability to advance its pipeline without near-term dilution. The wider loss reflects higher R&D outlays, which align with deliberate pipeline investment rather than any weakening in core operations. The $0.57 loss per share matched consensus estimates, so attention is likely to shift to forward commentary on upcoming clinical readouts.
Looking Ahead: Catalysts and Risks
Several items stand out for the coming quarters. The first-quarter 2027 clinical data readout is widely seen as a major potential catalyst. Positive results could reinforce the oral small-molecule GPCR strategy, while any disappointment might pressure sentiment. On the partnership side, Novo Nordisk is advancing candidates from Septerna’s research, including toxicity studies ahead of an IND filing. Continued milestones would bring additional non-dilutive revenue and confirm execution. Finally, spending discipline remains key. The $565.2 million cash balance offers a solid buffer, but rising R&D costs will need monitoring to keep the mid-2029 runway intact. From what I see, clinical outcomes will continue to drive long-term value more than quarterly financial fluctuations.
Using AI Tools in My Research
When reviewing biotech names like this, I often turn to Tickeron’s AI Screener for quick comparisons on fundamentals, technical patterns, and industry peers. It helps surface relevant data points without manual effort and supports a more efficient review of earnings-related factors. In my experience, combining these signals with traditional financial analysis provides a clearer picture of relative positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SEPN in upward trend: price rose above 50-day moving average on October 20, 2026
SEPN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 9 of 10 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SEPN as a result. In 24 of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for SEPN just turned positive on October 20, 2026. Looking at past instances where SEPN's MACD turned positive, the stock continued to rise in 7 of 10 cases over the following month. The odds of a continued upward trend are 70%.
The 10-day moving average for SEPN crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +10.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEPN advanced for three days, in 87 of 98 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
SEPN broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SEPN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.896) is normal, around the industry mean (3.498). SEPN has a moderately low P/E Ratio (-92.170) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (17.361) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SEPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement